Coya Therapeutics (COYA) EBITDA (2022 - 2026)

Coya Therapeutics has disclosed EBITDA across 5 years of filings, most recently posting -$7.0 million for Q2 2026.

• In Q2 2026, EBITDA fell 9.93% year-over-year to -$7.0 million; the TTM figure through Jun 2026 stood at -$23.1 million (down 2.38% YoY), while the FY2025 annual figure was -$22.5 million, down 30.81% from the prior year.
• EBITDA came in at -$7.0 million for Q2 2026 at Coya Therapeutics, up from -$7.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.8 million in Q4 2023 to a low of -$7.7 million in Q1 2025.
• Average EBITDA over 5 years is -$4.0 million, with a median of -$3.5 million recorded in 2022.
• Year-over-year, EBITDA surged 191.25% in 2023 and tumbled 323.57% in 2024.
• Over 5 years, EBITDA stood at -$2.0 million in 2022, then jumped by 191.25% to $1.8 million in 2023, then plunged by 323.57% to -$4.1 million in 2024, then tumbled by 47.89% to -$6.0 million in 2025, then dropped by 16.93% to -$7.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$7.0 million in Q2 2026, -$7.6 million in Q1 2026, and -$6.0 million in Q4 2025.